Abstract: A ropinirole-containing patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer comprising: at least one selected from the group consisting of ropinirole and a pharmaceutically acceptable salt thereof; at least one sodium carboxylate selected from the group consisting of sodium pentanoate, disodium glutarate, and sodium hexanoate; and an adhesive agent.

Abstract: An object of the present invention is to provide an asenapine-containing patch having excellent adhesiveness and handleability, which can persistently provide sufficient medicinal effects by suppressing cold flow during storage or application while enhancing skin permeability using a silicone-based pressure-sensitive adhesive base, and thereby maintaining the stability of the drug in the patch during storage, and maintaining an appropriate administration form for a long period of time. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and a silicone-based pressure-sensitive adhesive base, and the loss tangent (tan ?) of the pressure-sensitive adhesive layer is 0.75 to 1.5 at 1.0 Hz.

Abstract: A method for improving holding power of an adhesive agent layer in a ropinirole-containing patch comprising a backing layer and the adhesive agent layer, wherein the adhesive agent layer contains at least one selected from the group consisting of ropinirole and a pharmaceutically acceptable salt thereof and an adhesive agent, the method comprising: causing the adhesive agent layer to further contain a sodium salt of carbonic acid.

Abstract: A ropinirole-containing patch comprising an adhesive agent layer and a backing layer, wherein the adhesive agent layer containing: at least one selected from the group consisting of ropinirole and a pharmaceutically acceptable salt thereof; a fatty acid metal salt having 7 or more carbon atoms; and an adhesive agent.

Abstract: Since skin condition is significantly influenced by environmental factors associated with lifestyle habits, it has been difficult to forecast skin condition by means of SNP analysis. The purpose of the present invention is to determine one's congenital skin characteristics, which has been difficult with the prior art. The present invention provides a method for determining not only one's congenital skin characteristics but also future skin type by determining skin condition from genetic and environmental factors.

Abstract: Provided are a counseling method and counseling device which present a skincare advice appropriate to a user. The counseling device includes an obtaining unit that obtains genetic information representing a result of a genetic test on a user and stratum corneum information representing a result of a stratum corneum test on the user; a skin constitution determining unit that determines skin constitution of the user, based on the genetic information; a skin capability determining unit that determines skin capability representing a skin condition of the user, based on the stratum corneum information; an identifying unit that identifies a skincare advice and/or a cosmetic to be proposed to the user, based on the skin constitution and the skin capability; and a presenting unit that presents counseling information including information on the skincare advice and/or cosmetic to the user.

Abstract: An object of the present invention is to provide an asenapine-containing patch having excellent adhesiveness and handleability, which can persistently provide sufficient medicinal effects by suppressing cold flow during storage or application while enhancing skin permeability using a silicone-based pressure-sensitive adhesive base, and thereby maintaining the stability of the drug in the patch during storage, and maintaining an appropriate administration form for a long period of time. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and a silicone-based pressure-sensitive adhesive base, and the loss tangent (tan ?) of the pressure-sensitive adhesive layer is 0.75 to 1.5 at 1.0 Hz.

Abstract: The present invention provides a patch comprising a backing, and an adhesive layer on the backing, wherein the adhesive layer contains at least one drug selected from the group consisting of oxybutynin and a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive base, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0007 to 0.05% by mass based on the total mass of the adhesive layer.

Abstract: The present invention provides a patch comprising a backing and an adhesive layer laminated on one side of the backing, wherein the adhesive layer comprises asenapine or a pharmaceutically acceptable salt thereof, an adhesive base and a low molecular weight amine.

Abstract: The present invention provides a patch comprising a backing, and an adhesive layer on the backing, wherein the adhesive layer contains at least one drug selected from the group consisting of oxybutynin and a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive base, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0007 to 0.05% by mass based on the total mass of the adhesive layer.

Abstract: The present invention provides a patch comprising a backing and an adhesive layer laminated on one side of the backing, wherein the adhesive layer comprises asenapine or a pharmaceutically acceptable salt thereof, an adhesive base and a low molecular weight amine.

Abstract: A transdermal preparation comprising a multivalent metal chloride, a basic drug having an amino group, and an ester group-containing base material, is useful because of its excellent drug content stability.

Abstract: Wrinkles are improved by applying an oral preparation, injection preparation or external skin preparation having a substance that controls heparanase as an active ingredient thereof.

Abstract: A heparanase activity inhibitor containing, as an active ingredient, a 4-alkylresorcinol represented by formula (I): wherein R represents a C1-6 linear or branched alkyl group.

Abstract: A heparanase activity inhibitor comprising, as an active ingredient, a cyclic carboxamide derivative represented by formula (I): wherein n is an integer of 1 to 3, R1 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, X is —CH2— or a group represented by —N(R2)—, and R2 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, or a salt thereof.

Abstract: By providing a non-liquid drug reservoir layer 2 having first and second principal surfaces and containing a drug and a polymer that is to be a base, a drug permeation layer 4 disposed at the first principal surface side of the drug reservoir layer 2 and being lower in permeability of the drug than the drug reservoir layer 2, and a first backing 3 with a bending resistance of 10 to 80 mm that is formed so as to cover a side surface of the drug reservoir layer, skin irritation can be reduced.

Abstract: A heparanase activity inhibitor comprising, as an active ingredient, a cyclic carboxamide derivative represented by formula (I): wherein n is an integer of 1 to 3, R1 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, X is —CH2— or a group represented by —N(R2)—, and R2 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, or a salt thereof.

Abstract: A method for reducing the occurrence of wrinkles in skin caused by aging by promoting the growth of fibroblasts, which have a declined cellular proliferative potential due to aging or adverse affects from ultraviolet light or active oxygen. The method includes the steps of providing an agent that contains a yeast extract and a safflower extract as effective constituents, and applying the agent to skin to promote the growth of fibroblasts.

Abstract: A heparanase activity inhibitor comprising, as an active ingredient, a cyclic carboxamide derivative represented by formula (I): wherein n is an integer of 1 to 3, R1 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, X is —CH2— or a group represented by —N(R2)—, and R2 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, or a salt thereof.

Abstract: A transdermal absorption preparation having a support and a pressure-sensitive adhesive layer consisting of multiple layers, wherein the pressure-sensitive adhesive layer comprises a drug-retaining layer containing a drug and an acrylic pressure-sensitive adhesive and a skin adhesion layer containing a styrene-isoprene-styrene block copolymer. This preparation can continuously release bisoprolol at a constant concentration. Moreover, it can be easily produced.